Literature DB >> 21079194

The treatment of hyperphosphataemia in CKD: calcium-based or calcium-free phosphate binders?

Mario Cozzolino, Sandro Mazzaferro, Vincent Brandenburg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21079194     DOI： 10.1093/ndt/gfq691

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN： 0931-0509            Impact factor:   5.992


× No keyword cloud information.
  9 in total

1.  Gastrointestinal Inhibition of Sodium-Hydrogen Exchanger 3 Reduces Phosphorus Absorption and Protects against Vascular Calcification in CKD.

Authors:  Eric D Labonté; Christopher W Carreras; Michael R Leadbetter; Kenji Kozuka; Jill Kohler; Samantha Koo-McCoy; Limin He; Edward Dy; Deborah Black; Ziyang Zhong; Ingrid Langsetmo; Andrew G Spencer; Noah Bell; Desiree Deshpande; Marc Navre; Jason G Lewis; Jeffrey W Jacobs; Dominique Charmot
Journal:  J Am Soc Nephrol       Date:  2014-11-17       Impact factor: 10.121

2.  Sevelamer for hyperphosphataemia in kidney failure: controversy and perspective.

Authors:  Mario Cozzolino; Maria Antonietta Rizzo; Andrea Stucchi; Daniele Cusi; Maurizio Gallieni
Journal:  Ther Adv Chronic Dis       Date:  2012-03       Impact factor: 5.091

Review 3.  Management of Secondary Hyperparathyroidism in Chronic Kidney Disease: A Focus on the Elderly.

Authors:  Andrea Galassi; Paola Ciceri; Eliana Fasulo; Stefano Carugo; Giuseppe Cianciolo; Mario Cozzolino
Journal:  Drugs Aging       Date:  2019-10       Impact factor: 3.923

Review 4.  The role of phosphate in kidney disease.

Authors:  Marc G Vervloet; Siren Sezer; Ziad A Massy; Lina Johansson; Mario Cozzolino; Denis Fouque
Journal:  Nat Rev Nephrol       Date:  2016-11-21       Impact factor: 28.314

Review 5.  Preclinical Pharmacokinetics, Pharmacodynamics and Safety of Sucroferric Oxyhydroxide.

Authors:  Mario Cozzolino; Felix Funk; Viatcheslav Rakov; Olivier Phan; Isaac Teitelbaum
Journal:  Curr Drug Metab       Date:  2014       Impact factor: 3.731

Review 6.  Treatment of secondary hyperparathyroidism: the clinical utility of etelcalcetide.

Authors:  Mario Cozzolino; Andrea Galassi; Ferruccio Conte; Michela Mangano; Luca Di Lullo; Antonio Bellasi
Journal:  Ther Clin Risk Manag       Date:  2017-06-01       Impact factor: 2.423

7.  Therapeutic Effect of Iron Citrate in Blocking Calcium Deposition in High Pi-Calcified VSMC: Role of Autophagy and Apoptosis.

Authors:  Paola Ciceri; Monica Falleni; Delfina Tosi; Carla Martinelli; Stefania Cannizzo; Giulia Marchetti; Antonella D'Arminio Monforte; Gaetano Bulfamante; Geoffrey A Block; Piergiorgio Messa; Mario Cozzolino
Journal:  Int J Mol Sci       Date:  2019-11-25       Impact factor: 5.923

8.  Ferric Citrate, an Iron-Based Phosphate Binder, Reduces Health Care Costs in Patients on Dialysis Based on Randomized Clinical Trial Data.

Authors:  Roger A Rodby; Kausik Umanath; Robert Niecestro; T Christopher Bond; Mohammed Sika; Julia Lewis; Jamie P Dwyer
Journal:  Drugs R D       Date:  2015-09

Review 9.  Safety and effectiveness of lanthanum carbonate for hyperphosphatemia in chronic kidney disease (CKD) patients: a meta-analysis.

Authors:  Lijuan Zhao; An Liu; Guoshuang Xu
Journal:  Ren Fail       Date:  2021-12       Impact factor: 2.606
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.